

# 06 - References

## References

### Schizophrenia and related psychoses CHAPTER 1 References

1. Zohar J, et al. Neuroscience-based Nomenclature (NbN): a call for action. *World J Biol Psychiatry* 2016; 17:318-320.
2. National Institute for Health and Care Excellence. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Clinical guideline [CG76]. 2009 (last updated March 2019, last checked December 2024); <https://www.nice.org.uk/Guidance/CG76>.
3. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. 2014 (last checked November 2024); <https://www.nice.org.uk/guidance/cg178>.
4. Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; 353:1209-1223.
5. Jones PB, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUTLASS 1). *Arch Gen Psychiatry* 2006; 63:1079-1087.
6. Tandon R, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophr Res* 2008; 100:20-38.
7. Tarsy D, et al. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. *Handb Clin Neurol* 2011; 100:601-616.
8. Zhang JP, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. *Int J Neuropsychopharmacol* 2013; 16:1205-1218.
9. Zhu Y, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. *Lancet Psychiatry*; 4:694-705.
10. Leucht S, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry* 2009; 166:152-163.
11. Davis JM, et al. A meta-analysis of the efficacy of second-generation antipsychotics. *Archives of General Psychiatry* 2003; 60:553-564.
12. Leucht S, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009; 373:31-41.

13. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013; 382:951-962.
14. Huhn M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet* 2019; 394:939-951.
15. Voruganti L, et al. Neuroleptic dysphoria: towards a new synthesis. *Psychopharmacology (Berl)* 2004; 171:121-132.
16. Leucht S, et al. Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis. *World Psychiatry* 2023; 22:315-324.
17. Leucht S, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. *Am J Psychiatry* 2017; 174:927-942.
18. Siskind D, et al. Clozapine v. first- and second-generation antipsychotics in treatment--refractory schizophrenia: systematic review and meta- analysis. *Br J Psychiatry* 2016; 209:385-392.
19. Samara MT, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment--resistant schizophrenia: a network meta-analysis. *JAMA Psychiatry* 2016; 73:199-210.
20. Taylor DM. Clozapine for treatment-resistant schizophrenia: still the gold standard? *CNS Drugs* 2017; 31:177-180.
21. Kane JM, et al. The role of clozapine in treatment-resistant schizophrenia. *JAMA Psychiatry* 2016; 73:187-188.
22. Manu P, et al. Prediabetes in patients treated with antipsychotic drugs. *J Clin Psychiatry* 2012; 73:460-466.
23. Rummel-Kluge C, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2010; 123:225-233.
24. Sorensen HJ, et al. Schizophrenia, antipsychotics and risk of hip fracture: a population--based analysis. *Eur Neuropsychopharmacol* 2013; 23:872-878.
25. Trollor JN, et al. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. *Br J Psychiatry* 2012; 201:52-56.
26. Masopust J, et al. Risk of venous thromboembolism during treatment with antipsychotic agents. *Psychiatry Clin Neurosci* 2012; 66:541-552.
27. Pope A, et al. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. *Br J Psychiatry* 2010; 197:67-72.
28. Bailey L, et al. Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia: a systematic review of the literature. *Psychopharmacology (Berl)* 2019; 236:3081-3092.
29. Falkai P. Limitations of current therapies: why do patients switch therapies? *Eur Neuropsychopharmacol* 2008; 18 Suppl 3:S135-S139.
30. Yusufi B, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. *Int Clin Psychopharmacol* 2007; 22:238-243.
31. Day JC, et al. A comparison of patients' and prescribers' beliefs about neuroleptic side--effects: prevalence, distress and causation. *Acta Psychiatr Scand* 1998; 97:93-97.

32. Waddell L, et al. A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. *J Psychopharmacol* 2008; 22:238–243.
33. Ohlsen RI, et al. Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. *J Psychopharmacol* 2008; 22:323–329.

6 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1

34. Tiihonen J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ* 2006; 333:224.
35. Leucht C, et al. Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials. *Schizophr Res* 2011; 127:83–92.
36. Leucht S, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet* 2012; 379:2063–2071.
37. Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. *Lancet* 2022; 399:824–836.
38. Kane J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 1988; 45:789–796.
39. McEvoy JP, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 2006; 163:600–610.
40. Lewis SW, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. *Schizophr Bull* 2006; 32:715–723.
41. Stone JM, et al. Review: the biological basis of antipsychotic response in schizophrenia. *J Psychopharmacol* 2010; 24:953–964.
42. Agid O, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. *J Clin Psychiatry* 2011; 72:1439–1444.
43. Kahn RS, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. *Lancet Psychiatry* 2018; 5:797–807.

---

Revision #1

Created 2026-01-04 20:12:30 UTC by Omar Ayman

Updated 2026-01-04 20:12:30 UTC by Omar Ayman